Vaccines

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

With a year of strong growth, key partnerships, and pipeline progress, all eyes are on ALK's upcoming annual results for 2025.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

As AI pushes data centers to their limits, the optical industry gathers at OFC 2026 to unveil the power-efficient, high-speed networks of the future.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

The vaccine maker posts record 2025 earnings on mpox demand but signals a strategic shift, prioritizing its travel vaccine portfolio over new R&D.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

APhA awards honor the growing role of pharmacists in national immunization, highlighting innovation, dedication, and the future of community healthcare.

A landmark study of 2.8 million people unpacks the complex causes of food allergies, vindicates vaccines, and offers parents clarity on what they can control.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A Chinese biotech's novel nasal spray flu vaccine enters trials. Its unique design could finally make it safe for the elderly and expand global access.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.

A new subcutaneous autoinjector for Alzheimer's drug Leqembi could soon transform care for millions in China, moving treatment from hospital to home.